50 Recruiting Advanced Solid Tumor Phase 1 / Phase 2 Clinical Trials
Active phase 1 / phase 2 studies for advanced solid tumor enrolling across the USA. Verify eligibility and contact site coordinators.
All Advanced Solid Tumor studiesPhase 1 / Phase 2 Studies for Advanced Solid Tumor
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
š State University of Iowa ā Iowa City, Iowa
View Study & Checklist āA Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
š California Clinical Trials Medical Group (CCTMG) ā Glendale, California
View Study & Checklist āA Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
š MD Anderson Cancer Center ā Houston, Texas
View Study & Checklist āStudy of TTX-MC138 in Subjects With Advanced Solid Tumors
š Mary Crowley Cancer Center ā Dallas, Texas
View Study & Checklist āCFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
š The Ohio State University Comprehensive Cancer Center ā Columbus, Ohio
View Study & Checklist āA Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
š Moores Cancer Center, UCSD ā La Jolla, California
View Study & Checklist āSafety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
š Karmanos Cancer Center ā Detroit, Michigan
View Study & Checklist āFirst-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
š Site 139 ā Bullhead City, Arizona
View Study & Checklist āA Study to Investigate Safety and Tolerability of TransCon IL-2 Ī²/Ī³ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
š Ascendis Pharma Investigational Site ā Los Angeles, California
View Study & Checklist āLess Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
š START Midwest ā Grand Rapids, Michigan
View Study & Checklist āA Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
š Mayo Clinic ā Scottsdale, Arizona
View Study & Checklist āStudy of LP-184 in Patients With Advanced Solid Tumors
š Highlands Oncology Group ā Springdale, Arkansas
View Study & Checklist āNovel mRNA-LNP-Based Intratumoral Immunotherapy in Patients With Advanced Malignant Solid Tumors
š IntraAb Inc. ā Richmond, California
View Study & Checklist āPhase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors
š NEXT Oncology ā San Antonio, Texas
View Study & Checklist āStudy in Advanced Solid Tumor Patients
š DFCI ā Boston, Massachusetts
View Study & Checklist āA Study of YL242 in Subjects With Advanced Solid Tumors
š US-201 ā New Haven, Connecticut
View Study & Checklist āA Study of YL201 in Patients With Advanced Solid Tumors
š 002 ā Fair Oaks, California
View Study & Checklist āXTX301 in Patients With Advanced Solid Tumors
š University of California, Davis Comprehensive Cancer Center ā Sacramento, California
View Study & Checklist āStudy of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2RĪ± Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
š Sylvester Comprehensive Cancer Center - Miami ā Miami, Florida
View Study & Checklist āSafety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
š University of Alabama at Birmingham ā Birmingham, Alabama
View Study & Checklist āHyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors
š University of California, San Francisco ā San Francisco, California
View Study & Checklist āGI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
š Tisch Cancer Institute (TCI), Icahn School of Medicine ā New York, New York
View Study & Checklist āStudy of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
š University of Arizona Cancer Center ā Tucson, Arizona
View Study & Checklist āFirst-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
š Florida Cancer Specialists ā Sarasota, Florida
View Study & Checklist āA Study of LM-24C5 For Advanced Solid Tumors
š University of Southern California (USC) - Norris Comprehensive Cancer Center ā Los Angeles, California
View Study & Checklist āA Beta-only IL-2 ImmunoTherapY Study
š Sharp Memorial Hospital ā San Diego, California
View Study & Checklist āA Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
š Mayo Clinic in Arizona ā Scottsdale, Arizona
View Study & Checklist āA Study Evaluating OBI-902 in Participants With Advanced Solid Tumors
š Scripps Green Hospital ā La Jolla, California
View Study & Checklist āThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
š University of California Irvine Chao Family Comprehensive Cancer Center ā Irvine, California
View Study & Checklist āA Study of DB-1310 in Advanced/Metastatic Solid Tumors
š University of California, Davis Comprehensive Cancer Center ā Sacramento, California
View Study & Checklist āPhase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
š HonorHealth Research Institute ā Scottsdale, Arizona
View Study & Checklist āA First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
š Florida Cancer Specialists & Research Institute - Sarasota ā Sarasota, Florida
View Study & Checklist āA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
š Mayo Clinic Arizona ā Phoenix, Arizona
View Study & Checklist āStudy of SGN1 in Patients With Advanced Solid Tumor
š Banner MD Anderson Cancer Center ā Gilbert, Arizona
View Study & Checklist āStudy of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
š Cedars-Sinai Medical Center- Samuel Oschin Comprehensive Cancer Institute ā Los Angeles, California
View Study & Checklist āStudy of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
š South Texas Accelerated Research Therapeutics (START) - Midwest ā Grand Rapids, Michigan
View Study & Checklist āA Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
š Cleveland Clinic ā Cleveland, Ohio
View Study & Checklist āA First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
š D&H Cancer Research Center ā Margate, Florida
View Study & Checklist āA Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
š Emory University Winship Cancer Institute ā Atlanta, Georgia
View Study & Checklist āA Study of IDP-001 in Advanced or Metastatic Solid Tumors
š START Los Angeles ā Los Angeles, California
View Study & Checklist āEIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
š MD Anderson Cancer Center ā Houston, Texas
View Study & Checklist āA Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
š Clinical Trial Site ā Huntersville, North Carolina
View Study & Checklist āStudy of AVZO-021 in Patients With Advanced Solid Tumors
š Yale Cancer Center ā New Haven, Connecticut
View Study & Checklist āA Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
š University of Southern California ā Los Angeles, California
View Study & Checklist āA Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
š Horizon Oncology ā Lafayette, Indiana
View Study & Checklist āA Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
š START Mid-West ā Grand Rapids, Michigan
View Study & Checklist āA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
š H. Lee Moffitt Cancer Center & Research Institute ā Tampa, Florida
View Study & Checklist āPhase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
š HonorHealth Research and Innovation Institute ā Scottsdale, Arizona
View Study & Checklist āA Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
š Dana-Farber Cancer Institute ā Boston, Massachusetts
View Study & Checklist āA First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
š The University of Arizona Cancer Center ā Tucson, Arizona
View Study & Checklist ā